A Clinical Study to Evaluate Ayurvedic Decoctions with Local Oil Massage for Diabetic Peripheral Neuropathy

A Randomized Double Arm Comparative Clinical Study to Evaluate the Efficacy of Dashamula Kashaya and Mahamanjishtadi Kashaya Along with Sthanika Abhyanga in the Management of Prameha Upadrava vis a vis Diabetic Peripheral Sensory Neuropathy - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/104833

Enrollment

Registered

2026-02-26

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Subjects of Type 2 Diabetes Mellitus on OHA Oral Hypoglycaemic Agents with chronicity of 0to10 years will be included Subjects of Diabetic peripheral neuropathy with Diabetic Neuropathy Symptom Score - DNS 1to4 will be included Subjects with Diabetic peripheral neuropathy between the age group of 40 to 65 years irrespective of gender religion occupation and socioeconomic status will be included Subjects with HBA1C level upto 10percent will be included Subjects with FBS 120 to 200mg/dl PPBS 220 to 300 mg/dl will be included Definition of fresh cases include freshly diagnosed and untreated cases of Diabetic peripheral neuropathy Definition of treated cases includes already diagnosed and treated cases of Diabetic peripheral neuropathy who had voluntarily discontinued the treatment with the washout period of 7 days

Exclusion criteria

Exclusion criteria: Subjects of Type 2 Diabetes Mellitus on Insulin therapy and with complications like diabetic nephropathy retinopathy infectious wounds gangrene and foot ulcers will be excluded Subjects with age group below 40yrs and above 65yrs will be excluded Subjects with HbA1C above 10percent and chronicity more than 10 yrs will be excluded Subjects with uncontrolled diabetes mellitus ie FBS more than200mg/dL and PPBS more than 300 mg/dL will be excluded Subjects with any other systemic disorders which interfere with the intervention will be excluded Subjects with other type of neuropathy like Autonomic and motor neuropathy are excluded

Design outcomes

Primary

Measure	Time frame
TO KNOW THE REDUCTION IN TORONTO CLINICAL SCORING OF NEUROPATHY AND FBS PPBS HBA1C LEVELS Two Point Discrimination Test VAS scale for pain assessment Timepoint: 45 days	—

Secondary

Measure	Time frame
To know the reduction in Diabetic Neuropathy symptom scoreTimepoint: 45 days	—

Countries

India

Contacts

Public ContactDr Mohammad Yaseen Hullur

AYURVEDA MAHAVIDYALAYA AND HOSPITALHUBBALLI

yaseenhullur21@gmail.com8095744095

Outcome results